Inhibitory effects of melatonin on sulfatase and 17β-hydroxysteroid dehydrogenase activity and expression in glioma cells

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 1173-1178

  González, Alicia ^a   Martínez Campa, Carlos ^a   Mediavilla, Maria Dolores ^a   Alonso González, Carolina ^a   Álvarez García, Virginia ^a   Sánchez Barceló, Emilio José ^a   Cos, Samuel ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

17 hydroxysteroid dehydrogenase; Glioma cells; Melatonin; Pineal; Sulfatase

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN SULFATE; ESTRONE; MELATONIN; MESSENGER RNA; SULFATASE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME REGULATION; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; GLIOMA; MELATONIN; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFATASES;

EID: 77949473417     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000748     Document Type: Article

References (46)

1. Cos S and Sánchez-Barceló EJ: Melatonin and mammary pathological growth. Front Neuroendocrinol 21: 133-170, 2000.
2. Cos S and Sánchez-Barceló EJ: Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 15: 637-647, 2000.
3. Blask DE, Sauer LA and Dauchy RT: Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2: 113-132, 2002.
4. Sánchez-Barceló EJ, Cos S, Fernández R and Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr Relat Cancer 10: 153-159, 2003.
5. Sánchez-Barceló EJ, Cos S, Mediavilla MD, Martínez-Campa CM, González A and Alonso-González C: Melatonin-estrogen interactions in breast cáncer. J Pineal Res 38: 217-222, 2005.
6. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30: 118-128, 2006.
7. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 8: 691-702, 2008.
8. Cos S, Fernández R, Güezmes A and Sánchez- Barceló EJ: Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58: 4383-4390, 1998.
9. Cos S, Martínez-Campa C, Mediavilla MD and Sánchez- Barceló EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 38: 136-142, 2005.
10. 1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep 17: 947-955, 2007.
11. Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C and Sánchez- Barceló EJ: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118: 274-278, 2006.
12. Lee SJ and McEwen BS: Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu Rev Pharmacol Toxicol 41: 569-591, 2001.
13. Shy H, Malaiyandi L and Timiras PS: Protective action of 17β-estradiol and tamoxifen on glutamate toxicity in glial cells. Int J Dev Neurosci 18: 289-297, 2000.
14. Haghighat N, Oblinger MM and McCanless DW: Cytoprotective effect of estrogen on ammonium chloride-treated C6-glioma cells. Neurochem Res 29: 1359-1364, 2004.
15. McEwen B: Estrogen actions throughout the brain. Recent Prog Horm Res 57: 357-384, 2002.
16. Falkenstein E, Tillmann HC, Lost D, Feuring M and Lost D: Multiple actions of steroid hormones: a focus on rapid, nongenomic effects. Pharmacol Rev 52: 513-556, 2000.
17. Jung-Testas I, Renoir M, Bugnard H, Greene GL and Baulieu EE: Demonstration of steroid hormone receptors and steroid action in primary cultures of rat glial cells. J Steroid Biochem Mol Biol 41: 621-631, 1992.
18. Jung-Testas I, Schumacher M, Robel P and Baulieu EE: Actions of steroid hormones and growth factors on glial cells of the central and peripheral nervous system. J Steroid Biochem Mol Biol 48: 145-154, 1994.
19. Yague JG, Lavaque E, Carretero J, Azcoitia I and García-Segura LM: Aromatase, the enzyme responsable for estrogen biosynthesis, is expressed by human and rat glioblastomas. Neurosci Lett 368: 279-284, 2004.
20. Kriz L, Bicikova M, Mohapl M, Hill M, Ceny I and Hampl R: Steroid sulfatase and sulfuryl transferase activities in human brain tumors. J Steroid Biochem Mol Biol 109: 31-39, 2008.
21. Lephart ED: A review of brain aromatase cytochrome P450. Brain Res Rev 22: 1-26, 1996.
22. Cos S, Verduga R, Fernández-Viadero C, Megías M and Crespo D: Effects of melatonin on the proliferation and differentiation of human neuroblastoma cells in culture. Neurosci Lett 216: 113-116, 1996.
23. Armstrong KJ and Niles LP: Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells. Neuroreport 13: 473-475, 2002.
24. Feng Z and Zhang JT: Protective effect of melatonin on βamylod-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic Bio Med 37: 1790-1801, 2004.
25. Rincón Castro LM, Gallant M and Niles LP: Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 95: 1227-1236, 2005.
26. Martín V, Herrera F, Carrera-González P, García-Santos G, Antolín I, Rodríguez-Blanco J and Rodríguez C: Intracellular signaling pathways envolved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 66: 1081-1088, 2006.
27. Herrera F, Martin V, García-Santos G, Rodriguez-Blanco J, Antolín I and Rodríguez C: Melatonin prevents glutamate-induced oxytosis in the HT22 mouse hippocampal cells line through an antioxidant effect specifically targeting mitochondria. J Neurochem 100: 736-746, 2007.
28. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V and Maestroni G: Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53: 43-46, 1996.
29. Kim B, Rincón Castro LM, Jawed S and Niles LP: Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. Eur J Pharmacol 589: 45-48, 2008.
30. Martín V, Herrera F, García-Santos G, Antolín I, Rodríguez-Blanco J, Medina M and Rodríguez C: Involvement of protein kinase C in melatonin's oncostatic effect in C6 glioma cells. J Pineal Res 43: 239-244, 2007.
31. Kolber AR, Perumal AS, Goldstein MN and Moore BW: Drug-induced differentiation of a rat glioma in vitro: II. The expression of S-100, a glial specific protein and steroid sulfatase. Brain Res 143: 513-520, 1978.
32. Kitawaki J, Fukuoka M, Yamamoto T, Honjo H and Okada H: Contribution of aromatase to the deoxyribonucleic acid synthesis of MCF-7 human breast cancer cells and its suppression by aromatase inhibitors. J Steroid Biochem Mol Biol 42: 267-277, 1992.
33. González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells. Br J Cancer 97: 755-760, 2007.
34. Duncan L, Purohit A, Howarth NM, Potter BV and Reed MJ: Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. Cancer Res 53: 298-303, 1993.
35. Singh A and Reed MJ: Insulin-like growth factor type I and insulin-like growth factor type II stimulate oestradiol-17 beta hydroxysteroid dehydrogenase (reductive) activity in breast cancer cells. J Endocrinol 129: 5-8, 1991.
36. Huang K, Whelan EA, Ruder AM, Ward EM, Deddens JA, Davis-King KE, Carreon T, Waters MA, Butler MA, Calvert GM, Schulte PA, Zivkovich Z, Heineman EF, Mandel JS, Morton RF, Reding DJ, Rosenman KD and The Brain Cancer Collaborative Study Group: Reproductive factors and risk of glioma in women. Cancer Epidemiol Biomarkers Prev 13: 1583-1588, 2004.
37. Inskip PD, Linet MS and Heineman EF: Etiology of brain tumors in adults. Epidemiol Rev 17: 382-414, 1995.
38. Stoffel-Wagner B: Neurosteroid biosynthesis in the human brain and its clinical implications. Ann NY Acad Sci 1007: 64-78, 2003.
39. Del Rio B, García-Pedrero JM, Martínez-Campa C, Zuazua P, Lazo PS and Ramos S: Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 279: 38294-38302, 2004.
40. González A, Cos S, Martínez-Campa C, Alonso-González C, Sánchez-Mateos S, Mediavilla MD and Sánchez-Barceló EJ: Selective estrogen enzime modulator (SEEM) actions of melatonin in human breast cancer cells. J Pineal Res 45: 86-92, 2008.
41. Martínez-Campa CM, González A, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Res Treat 94: 249-254, 2005.
42. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L and Reiter RJ: Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63: 29-43, 2005.
43. García-Santos G, Antolín I, Herrera F, Martín V, Rodríguez-Blanco J, Carrera P and Rodríguez C: Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 41: 130-135, 2006.
44. Longatti P, Perin A, Rizzo V, Comai S, Giusti P and Costa CVL: Ventricular cerebrospinal fluid melatonin concentrations investigated with an endoscopic technique. J Pineal Res 42: 113-118, 2007.
45. Pasqualini JR and Chetrite GS: Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93: 221-236, 2005.
46. Frungieri MB, Mayerhofer A, Zitta K, Pignataro OP, Calandra RS and González-Calvar SI: Direct effect of melatonin on Syrian hamster testes: melatonin subtype 1a receptors, inhibition of androgen production, and interaction with the local corticotropin-releasing hormone system. Endocrinology 146: 1541-1552, 2005.